A phase II, non-randomized, multi-center study to evaluate the efficacy and safety of pazopanib (GW786034) in subjects with advanced non-small cell lung cancer.

Trial Profile

A phase II, non-randomized, multi-center study to evaluate the efficacy and safety of pazopanib (GW786034) in subjects with advanced non-small cell lung cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2014

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 Jan 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 24 Jun 2009 Actual end date (1 Apr 2009) added as reported by ClinicalTrials.gov.
    • 24 Jun 2009 Actual patient number (14) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top